ASCO24 Updates: Lucas Moreno on Therapies for High-Risk Neuroblastoma
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in the field of oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.
This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on-site. We had the pleasure of interviewing researchers who summarized the highlights of their work.
In this video, Lucas Moreno Division Head of Paediatric Oncology and Haematology at Vall d’Hebron Barcelona Hospital Campus, shared insights on ‘Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma: A BEACON-Neuroblastoma biomarker study.‘
Hello, I’m Lucas Moreno. I’m a pediatric oncologist based in Vall d’Hebron Comprehensive Cancer Center in Barcelona and I mainly work in the field of pediatric solid tumors and early phase clinical trials, particularly in a tumor that is neuroblastoma, one of the most common and still and yet aggressive pediatric cancers.
I’m going to be part of an educational session tomorrow, Monday at ASCO, where we are going to dive in into what do we do when patients don’t respond well to the induction chemotherapy, where we’re going to discuss the options that follow after a poor response to induction, such as bridging therapies, so-called bridging therapies that can include chemotherapy, chemoimmunotherapy, and MIBG therapy
And then also what options follow afterwards, such as consolidation with high-dose chemotherapy with stem cell transplant, single or tandem transplant, and then how to follow afterwards and still describe the challenges that we face these days and what the international cooperative groups across the world, such as the Children’s Oncology Group in North America or COPEN in Europe, have to try to improve outcomes for the population of children that have high-risk neuroblastoma and don’t respond well to therapies.
So in summary, we will host an educational session focused on bridging therapies and consolidation therapies for children with high-risk neuroblastoma, which we hope will be enlightening and help us in the future.
More videos and content from ASCO 2024 on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023